Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 4/20 | 0.47 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 3/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | USP5 | P45974 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346088 | 0.73 | CTSS (0.68) | CTSSCTSKACLYCTSBCYP2C19 | |
| SCHEMBL346086 | 0.73 | CTSS (0.68) | CTSSCTSKACLYCTSBCYP2C19 | |
| SCHEMBL345227 | 0.70 | CTSB (0.43) | CTSSCTSKCTSBCYP2C19CYP2D6 | |
| SCHEMBL346538 | 0.70 | CTSS (0.67) | CTSSCTSKACLYCTSBCYP2C19 | |
| SCHEMBL346536 | 0.70 | CTSS (0.67) | CTSSCTSKACLYCTSBCYP2C19 | |
| SCHEMBL1371404 | 0.65 | CTSS (0.40) | CTSSCTSKACLYCYP2C19CYP2D6 | |
| SCHEMBL12891813 | 0.65 | CTSS (0.38) | CTSSCTSKACLYCTSBCYP2C19 | |
| Trifluoroacetic Acid SCHEMBL4064667 | 0.61 | CPB2 (0.37) | CYP2C19CYP1A2TSHR | |
| Trifluoroacetic Acid SCHEMBL31726675 | 0.60 | FKBP1A (0.37) | MEN1TSHRKMT2A | |
| SCHEMBL12452754 | 0.60 | CTSS (0.36) | CTSSCTSKCYP2C19CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
| US-8039480-B2 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2011-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | CTSS 24/4885CTSK 87/4885ACLY 2814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.